Statistiche di base
| CIK | 1127354 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DNAPrint Genomics, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| February 9, 2009 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2009 DNAPrint Genomics, Inc. (Exact name of registrant as specified in its charter) Utah 0-31905 59-2780520 (State or Other Jurisdiction (Commission (I.R.S. |
|
| April 4, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2008 DNAPrint Genomics, Inc. (Exact name of registrant as specified in its charter) Utah 0-31905 59-2780520 (State or Other Jurisdiction (Commission (I.R.S. Employer of Inco |
|
| March 3, 2008 |
8K DNA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2008 DNAPrint Genomics, Inc. (Exact name of registrant as specified in its charter) Utah 0-31905 59-2780520 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| February 4, 2008 |
Nanobac Pharmaceuticals, Incorporated 4730 North Habana Avenue Suite 205 Tampa, Florida 33614 Ex 99.1 EXHIBIT 99.01 Nanobac Pharmaceuticals, Incorporated 4730 North Habana Avenue Suite 205 Tampa, Florida 33614 January 18, 2008 Dr. Hector Gomez Chairman of the Board DNA Print Genomics 1621 W University Parkway Sarasota, Florida 34243 Dear Dr. Gomez: The purpose of this letter is to confirm the recent discussions and an agreement in principle between Nanobac Pharmaceuticals, Incorporated (“B |
|
| February 4, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. February 1, 2008 Date of Report (Date of Earliest Event Reported) DNAPrint Genomics, Inc. (Exact name of registrant as specified in charter) Utah 0-31905 59-2780520 (State or other jurisdiction of incorporation) (Commission File |
|
| February 4, 2008 |
Nanobac Pharmaceuticals, Incorporated 4730 North Habana Avenue Suite 205 Tampa, Florida 33614 Nanobac Pharmaceuticals, Incorporated EXHIBIT 99.02 Nanobac Pharmaceuticals, Incorporated 4730 North Habana Avenue Suite 205 Tampa, Florida 33614 February 1, 2008 Dr. Hector Gomez Chairman of the Board DNA Print Genomics 1621 W University Parkway Sarasota, Florida 34243 Dear Dr. Gomez: The purpose of this letter is to confirm the recent discussions and to amend our agreement in principle between N |
|
| December 28, 2007 |
Schedule 13D CUSIP No. 2332 4Q 20 2 13G Page 1 of 5 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) DNAPrint Genomics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 2332 4Q 202 (CUSIP Number) December 27, 2007 (Date of Event which Requires Filing of this Statement) Check the |
|
| December 28, 2007 |
Schedule 13D CUSIP No. 2332 4Q 20 2 13G Page 1 of 5 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) DNAPrint Genomics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 2332 4Q 202 (CUSIP Number) December 27, 2007 (Date of Event which Requires Filing of this Statement) Check the |
|
| December 28, 2007 |
Schedule 13D CUSIP No. 2332 4Q 20 2 13D Page 1 of 5 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6 ) DNAPrint Genomics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 2332 4Q 202 (CUSIP Number) Tony N. Frudakis 1621 West University Parkway Sarasota, Florida 34243 (Name, Address |
|
| December 21, 2007 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DNAPrint Genomics, Inc. (Exact name of registrant as specified in charter) UTAH 59-2780520 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 1621 W. University Parkway, Sarasota, FL 34243 (Address of principal executive offices) Consultant C |
|
| December 20, 2007 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. Date of Report (Date of Earliest Event Reported) December 14, 2007 DNAPrint Genomics, Inc. (Exact name of registrant as specified in charter) Utah 0-31905 59-2780520 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 14, 2007 | ||
| November 14, 2007 | ||
| November 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended September 30, 2007. [ ] Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . DNAPrint Genomics, Inc. (Exact name of registrant as speci |
|
| August 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended June 30, 2007. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-31905 DNAPrint Genomics, Inc. (Exact |
|
| August 9, 2007 |
As Filed with the Securities and Exchange Commission on August 9, 2007 REGISTRATION NO. |
|
| August 8, 2007 |
FILE NO. 48288.113726 August 8, 2007 VIA EDGAR CORRESPONDENCE, FACSIMILE and U.S. MAIL Gregory S. Belliston, Esq. Division of Corporation Finance U.S. Securities and Exchange Commission Mail Stop 6010 100 F Street, N.E. Washington, D.C. 20549 Re: DNAPrint Genomics, Inc. Registration Statement on Form SB-2, Amendment 3 File No. 333-141991 Dear Mr. Belliston: As a follow up to my letter yesterday, I |
|
| August 8, 2007 |
SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| August 8, 2007 |
FIRMLTR FILE NO. 48288.113726 August 7, 2007 VIA EDGAR VIA FACSIMILE and U.S. MAIL Gregory S. Belliston, Esq. Division of Corporation Finance U.S. Securities and Exchange Commission Mail Stop 6010 100 F Street, N.E. Washington, D.C. 20549 Re: DNAPrint Genomics, Inc. Registration Statement on Form SB-2, Amendment 3 File No. 333-141991 Dear Mr. Belliston: This letter is written in response to your c |
|
| August 8, 2007 |
REQUEST FOR ACCELERATION OF THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT ON FORM SB-2 REQUEST FOR ACCELERATION REQUEST FOR ACCELERATION OF THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT ON FORM SB-2 The undersigned, DNAPrint Genomics, Inc. |
|
| August 8, 2007 |
EXHIBIT 10.66 Dutchess Capital Management, Ltd. 50 Commonwealth Ave. Suite 2 Boston, MA 02116 July 20, 2007 DNAPrint Genomics, Inc. 1621 West University Parkway Sarasota, FL 34243 Ladies and Gentlemen: The parties acknowledge the accuracy of the following facts: 1. DNAPrint Genomics, Inc. ("DNAPrint") is a party to an Investment Agreement dated March 30, 2007, with Dutchess Private Equities Fund, |
|
| August 2, 2007 |
PLEASE REPLY TO CLEARWATER FILE NO. 48288.113726 August 1, 2007 VIA FACSIMILE and U.S. MAIL Gregory S. Belliston, Esq. Division of Corporation Finance U.S. Securities and Exchange Commission Mail Stop 6010 100 F Street, N.E. Washington, D.C. 20549 Re: DNAPrint Genomics, Inc. Amendment No. 3 to Form SB-2 File No. 333-141991 Dear Mr. Belliston: Attached for your review and consideration is Amendment |
|
| August 2, 2007 |
As Filed with the Securities and Exchange Commission on August 2, 2007 REGISTRATION NO. |
|
| July 30, 2007 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. July 24, 2007 Date of Report (Date of Earliest Event Reported) DNAPrint Genomics, Inc. (Exact name of registrant as specified in charter) Utah 0-31905 59-2780520 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 13, 2007 |
JOHNSON POPE, BOKOR, RUPPEL & BURNS, LLP ATTORNEYS AND COUNSELLORS AT LAW JOHNSON POPE, BOKOR, RUPPEL & BURNS, LLP ATTORNEYS AND COUNSELLORS AT LAW PLEASE REPLY TO CLEARWATER FILE NO. |
|
| July 9, 2007 |
Schedule 13D Gomez CUSIP No. 2332 4Q 20 2 13G Page 1 of 5 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) DNAPrint Genomics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 2332 4Q 20 2 (CUSIP Number) June 27, 2007 (Date of Event which Requires Filing of this Statement) Check |
|
| July 9, 2007 |
Schedule 13D Gabriel CUSIP No. 2332 4Q 20 2 13G Page 1 of 4 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) DNAPrint Genomics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 2332 4Q 20 2 (CUSIP Number) June 27, 2007 (Date of Event which Requires Filing of this Statement) Chec |
|
| July 9, 2007 |
Schedule 13D Frudakis CUSIP No. 13D Page 1 of 4 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5 ) DNAPrint Genomics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 2332 4Q 202 (CUSIP Number) Tony N. Frudakis 1621 West University Parkway Sarasota, Florida 34243 (Name, Address and |
|
| July 3, 2007 |
July 2, 2007 Jeffrey Reidler, Esq. Assistant Director Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549 Re: DNAPrint Genomics, Inc. Registration Statement on Form SB-2 File No. 333-141991 Ladies and Gentlemen: We have been retained as special counsel to assist DNAPrint Genomics, Inc. (?DNAPrint? or ?Company?) in the pro |
|
| July 3, 2007 |
As Filed with the Securities and Exchange Commission on July 3, 2007 REGISTRATION NO. |
|
| June 4, 2007 |
DNAPrint SB-2 As Filed with the Securities and Exchange Commission on June 4, 2007 REGISTRATION NO. |
|
| June 4, 2007 |
PRODUCT DISTRIBUTION AGREEMENT Exhibit 10.32 Exhibit 10.32 PRODUCT DISTRIBUTION AGREEMENT THIS PRODUCT DISTRIBUTION AGREEMENT (the “Agreement”) is made and entered into this 18thday of October, 2005 (the “Effective Date”) by and between DNAPrint Genomics, Inc., (the “Company”), and Sorenson Genomics, LLC (dba Relative Genetics) a Utah limited liability company located at 2495 South West Temple Salt Lake City, UT 84115 USA (the |
|
| June 4, 2007 |
June 4, 2007 Jeffrey Reidler, Esq. Assistant Director Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549 Re: DNAPrint Genomics, Inc. Registration Statement on Form SB-2 File No. 333-141991 Ladies and Gentlemen: We have been retained as special counsel to assist DNAPrint Genomics, Inc. (?DNAPrint? or ?Company?) in the pro |
|
| May 14, 2007 | ||
| May 14, 2007 | ||
| May 14, 2007 | ||
| May 14, 2007 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.62 Exhibit 10.62 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into this 27th day of April, 2007, by and between DNAPrint Genomics, Inc., a Utah corporation (the "Company"), and Karen Surplus, I/C/O 1621 West University Parkway, Sarasota, FL 34243 (the "Executive"). W I T N E S S E T H: WHEREAS, the Company and the Executive desire |
|
| May 14, 2007 | ||
| May 14, 2007 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.63 Exhibit 10.63 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into this 27th day of April, 2007, by and between DNAPrint Pharmaceuticals, Inc., a Florida corporation (the "Company"), and Richard Gabriel, I/C/O 1621 West University Parkway, Sarasota, FL 34243 (the "Executive"). W I T N E S S E T H: WHEREAS, the Company and the Execu |
|
| May 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended March 31, 2007. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-31905 DNAPrint Genomics, Inc. (Exact |
|
| May 14, 2007 | ||
| April 30, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. April 27, 2007 Date of Report (Date of Earliest Event Reported) DNAPrint Genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S. Employer |
|
| April 30, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 10, 2007 | ||
| April 10, 2007 |
As Filed with the Securities and Exchange Commission on April 10, 2007 REGISTRATION NO. |
|
| April 10, 2007 |
REGISTRATION RIGHTS AGREEMENT Exhibit 10.58 REGISTRATION RIGHTS AGREEMENT Registration Rights Agreement (the “Agreement”), dated as of March 30, 2007, by and between DNAPrint Genomics, Inc., a corporation organized under the laws of State of Utah, with its principal executive office at 1621 West University Parkway, Sarasota FL 34243 (the “Company”), and Dutchess Private Equities Fund, Ltd., a Caym |
|
| March 15, 2007 |
Engagement Letter Exhibit 10.53 CONFIDENTIAL January 22, 2007 Richard Gabriel, CEO and Hector Gomez, M.D., Ph. D., Chairman DNAP Genomics, Inc. 1621 W. University Parkway Sarasota, FL 34243 Gentlemen: This letter agreement (the “Agreement”) shall confirm the engagement of Athena Capital Partners, Inc. (“Athena”) by DNAPrint Genomics, Inc. and any of its subsidiaries and affiliates (hereinafter ref |
|
| March 15, 2007 | ||
| March 15, 2007 |
Form 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) [ X ] ANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2006. [ ] TRANSITION REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 0-31905 DNAPrint Ge |
|
| March 15, 2007 | ||
| March 15, 2007 | ||
| March 15, 2007 |
Credit Agreement providing usual securities Clientis Exhibit 10.50 Clientis Ersparniskasse Erlinsbach Credit Agreement providing usual securities 1. Parties to the Agreement and credit amount CLIENTIS Ersparnisbank Erlinsbach, Erlinsbach (hereinafter called the “bank”) hereby grants to DNAPrint genomics, Inc., 900 Cocoanut Avenue, Sarasota, FL 34236 USA (hereinafter called the “borrower”) a current account credit up to a maximum amount of C |
|
| March 15, 2007 | ||
| March 5, 2007 |
Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2007 DNAPrint Genomics, Inc. (Exact name of registrant as specified in its charter) UT 000-31905 59-2780520 (State or other jurisdiction of incorporation) (Commission File |
|
| February 16, 2007 |
EXHIBIT 10.1 CERTIFICATE OF CORPORATE OFFICER DNAPRINT GENOMICS, INC. Compensation of Consultant, Dr. Arthur Sytkowski I, the undersigned, hereby certify that (i) I am the duly appointed officer of DNAPrint Genomics, Inc. a Utah corporation (the “Company”); (ii) I am duly authorized to execute this Certificate for and on behalf of the Company; and (iii) based upon my personal knowledge, I confirm |
|
| February 16, 2007 |
Amy Trombly 1320 Centre Street, Suite 202 Newton, Massachusetts 02459 EXHIBIT 10.2 Amy Trombly 1320 Centre Street, Suite 202 Newton, Massachusetts 02459 Richard Gabriel Chief Executive Officer DNAPrint Genomics, Inc. 1621 W. University Parkway Sarasota, FL 34243 February 16, 2007 Dear Mr. Gabriel, This letter is to document our agreement that DNAPrint Genomics ( “DNAPrint”) will pay for legal services in registered common stock. We agreed that I will be issued up to |
|
| February 16, 2007 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DNAPrint Genomics, Inc. (Exact Name of Registrant as Specified in its Charter) UTAH 59-2780520 (State of Incorporation) (I.R.S. Employer ID No.) 1621 W. University Parkway, Sarasota, FL 34243 (Address of principal executive offices) Consultant Compensation (Full title of |
|
| February 16, 2007 | ||
| November 15, 2006 |
As Filed with the Securities and Exchange Commission on November 15, 2006 As Filed with the Securities and Exchange Commission on November 15, 2006 REGISTRATION NO. |
|
| November 15, 2006 |
Amy M. Trombly, Esq. [email protected] November 15, 2006 Delivered by electronic submission via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 7010 Washington, DC 20549 Attn: Mr. Jeffrey Riedler Re: DNAPrint Genomics, Inc. Registration Statement on Form SB-2 File Number: 333-137323 Dear Mr. Riedler: I am securities coun |
|
| November 13, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended September 30, 2006. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-31905 DNAPrint Genomics, Inc. (E |
|
| March 29, 2006 |
Exhibit 10.40 SECURITY AGREEMENT SECURITY AGREEMENT (this “Agreement”), dated as of March 13, 2006, by and among DNAPrint Genomics, Inc., a Utah corporation (“Company”), and Dutchess Private Equities Fund, LP, a Delaware Limited partnership, as the secured parties signatory hereto and their respective endorsees, transferees and assigns (collectively, the “Secured Party”). W I T N E S S E T H: WHER |
|
| March 29, 2006 |
RESEARCH SPONSORSHIP AGREEMENT Exhibit 10.37 RESEARCH SPONSORSHIP AGREEMENT This Research Sponsorship Agreement is made and entered this 31st day of January , 2006 (“Effective Date”), by and between DNAPrint Genomics, Inc. a corporation organized and existing under the laws of Utah and having its principal offices at 900 Cocoanut Ave., Sarasota FL 34231 (“Company”) and Massachusetts College of Pharmacy and Health Sciences, 179 |
|
| March 29, 2006 |
BY-LAWS CATALYST COMMUNICATIONS, INC. ARTICLE I Share Certificates and Transfer BY-LAWS OF CATALYST COMMUNICATIONS, INC. ARTICLE I Share Certificates and Transfer Section 1. Certificates: Certificates representing the shares of capital stock of this Corporation shall be printed or engraved in such form and contain such recitals, signatures and seals as required by law, or to the extent not in conflict therewith, as may be determined by the Board of Directors, Every Shareholde |
|
| March 29, 2006 |
Exhibit 10.39 PROMISSORY NOTE FACE AMOUNT $1,500,000 PRICE $1,200,000 INTEREST RATE 0% per month NOTE NUMBER March-2006-101 ISSUANCE DATE March 13, 2006 MATURITY DATE March 6, 2007 FOR VALUE RECEIVED, DNAPrint Genomics, Inc., a Utah corporation (the “Company”) (OTC BB: DNAG) hereby promises to pay to the order of DUTCHESS PRIVATE EQUITIES FUND, L.P. (collectively, the “Holder”) by the Maturity Dat |
|
| March 29, 2006 |
FINANCIAL CONSULTING AGREEMENT Exhibit 10.38 FINANCIAL CONSULTING AGREEMENT This agreement is made by and between DNAPrint Genomics, Inc., a Utah based corporation having its principle office at 900 Cocoanut Avenue, Sarasota, Florida 34236 (the “COMPANY”), and Market Pulse LLC, having its principle office at 4221 Potters Walk, Atlanta, Georgia 30342 (the “CONSULTANT”). In consideration of the mutual promise contained herein and |
|
| March 29, 2006 |
FINANCIAL CONSULTING AGREEMENT Exhibit 10.34 FINANCIAL CONSULTING AGREEMENT This agreement is made by and between DNAPrint genomics, Inc., a Utah based corporation having its principle office at 900 Cocoanut Avenue, Sarasota, Florida 34236 (the “COMPANY”), and Market Pulse LLC, having its principle office at 4221 Potters Walk, Atlanta, Georgia 30342 (the “CONSULTANT”). In consideration of the mutual promise contained herein and |
|
| March 29, 2006 |
Exhibit 10.35 PROMISSORY NOTE FACE AMOUNT $1,380,000 PRICE $1,150,000 INTEREST RATE 0% per month NOTE NUMBER December-2005-101 ISSUANCE DATE December 22, 2005 MATURITY DATE December 15, 2006 FOR VALUE RECEIVED, DNAPrint Genomics, Inc., a Utah corporation (the ?Company?), (OTC BB: DNAG) hereby promises to pay to the order of DUTCHESS PRIVATE EQUITIES FUND, II, L.P. (the ?Holder?) by the Maturity Da |
|
| March 29, 2006 |
RESTATED ARTICLES OF INCORPORATION DNAPRINT GENOMICS, INC. RESTATED ARTICLES OF INCORPORATION OF DNAPRINT GENOMICS, INC. DNAPrint Genomics, Inc., a corporation organized and existing under and by virtue of the Laws of the State of Utah (the “Corporation”), pursuant to Section 16-10a-1007 of the Utah Business Corporation Act, does hereby certify that the Board of Directors of the Corporation has adopted a resolution setting forth these restated Articles of |
|
| March 29, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) xANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2005. oTRANSITION REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 0-30119 DNAPrint Genomics, Inc. (Name o |
|
| March 29, 2006 |
Exhibit 10.33 PROMISSORY NOTE FACE AMOUNT $1,380,000 PRICE $1,150,000 INTEREST RATE 0% per month NOTE NUMBER October -2005-101 ISSUANCE DATE November 18, 2005 MATURITY DATE December 31, 2006 FOR VALUE RECEIVED, DNAPrint Genomics, Inc., a Utah corporation (the “Company”), (OTC BB: DNAG) hereby promises to pay to the order of DUTCHESS PRIVATE EQUITIES FUND, L.P. (the “Holder”) by the Maturity Date, |
|
| February 28, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. February 22, 2006 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S. Emplo |
|
| February 7, 2006 |
Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. January 31, 2006 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S. Employer I.D. No) 900 Cocoanut Avenue, Sarasota, FL 342 |
|
| January 27, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. January 24, 2006 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S. Employ |
|
| January 27, 2006 |
RESEARCH SPONSORSHIP AND LICENSE AGREEMENT RESEARCH SPONSORSHIP AND LICENSE AGREEMENT Effective this 24th day of January, 2006 (“EFFECTIVE DATE”), President and Fellows of Harvard College, a charitable corporation of Massachusetts having an office at 25 Shattuck Street, Boston, MA 02115 (“HARVARD”), and DNAPrint Genomics, Inc. |
|
| December 29, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. December 22, 2005 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S. Employ |
|
| December 23, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. December 19, 2005 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S Employ |
|
| November 28, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. November 21, 2005 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S. Emplo |
|
| November 15, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. November 8, 2005 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S. Employ |
|
| June 24, 2005 |
SCHEDULE 13G OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| June 24, 2005 |
SCHEDULE 13G OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| May 11, 2005 |
SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement. |
|
| May 5, 2005 |
Unassociated Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| May 5, 2005 |
Unassociated Document LICENSE AGREEMENT by and between The Beth Israel Deaconess Medical Center and DNAPrint Genomics, Inc. |
|
| April 25, 2005 |
Unassociated Document SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary proxy statement. |
|
| April 11, 2005 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-30119 S.D.E. Holdings 1, Inc. (Exact name of registrant as specified in its charter |
|
| April 8, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. April 4, 2005 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of Registrant as specified in charter) Commission File Number: 0-31905 Utah 59-2780520 (State of Incorporation) (I.R.S. Employer |
|
| March 24, 2005 |
dOMB APPROVAL OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| March 24, 2005 |
SCHEDULE 13G OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response. |
|
| November 15, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended September 30, 2004. [] Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-31905 DNAPrint genomics, Inc. (Ex |
|
| October 5, 2004 |
JOINT VENTURE FRAMEWORK AGREEMENT between Biofrontera Pharmaceuticals GmbH, Hemmelrather Weg 201, 51377 Leverkusen, Germany including its affiliated companies Biofrontera AG and Biofrontera Discovery GmbH - Biofrontera - and DNAPrint genomics Inc. |
|
| October 5, 2004 |
DNAPrint INVESTMENT AGREEMENT DATED September 28, 2004 relating to Biofrontera AG ALLEN & OVERY LLP Frankfurt 10. |
|
| October 5, 2004 |
September 30, 2004 Mr. Richard Gabriel President & CEO DNAPrint genomics, Inc. 900 Cocoanut Avenue Sarasota, FL 34236 Dear Mr. Gabriel: This will confirm our understanding that The Wall Street Group, Inc. ("WSG") has been retained as financial public relations counsel to DNAPrint genomics, Inc. ("DNAPrint"), beginning September 30, 2004 and continuing until cancelled as hereinafter provided. As co |
|
| October 5, 2004 |
Unassociated Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| October 5, 2004 |
REGISTRATION RIGHTS AGREEMENT Registration Rights Agreement (the "Agreement"), dated as of September 28, 2004, by and between DNAPrint Genomics, Inc. |
|
| October 5, 2004 |
INVESTMENT AGREEMENT INVESTMENT AGREEMENT (this "AGREEMENT"), dated as of September 28, 2004 by and between DNAPrint Genomics, Inc. |
|
| August 13, 2004 |
FIRST AMENDMENT TO DNAPRINT GENOMICS INC. 2001 SCIENTIST STOCK OPTION PLAN WHEREAS, Board of Directors has previously adopted the DNAPrint genomics, Inc. 2001 Scientist Stock Option Plan (the "Plan"); and WHEREAS, pursuant to Section 14(a) of the Plan, the Board of Directors may amend the Plan; and WHEREAS, the Board of Directors desires to amend the Plan in certain respects. NOW, THEREFORE, the B |
|
| August 13, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB Unassociated Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| July 1, 2004 |
SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary proxy statement. |
|
| March 30, 2004 |
EX-10.42 Amendment to Funding Agreement EXHIBIT 10.42 AMENDMENT This Amendment to Funding Agreement is entered into as of the 30th day of December, 2003, by and between Tony Frudakis ("Investor") and DNAPRINT genomics, Inc. (the "Company"). W I T N E S S E T H: WHEREAS, the parties hereto are parties to a Funding Agreement dated on or about October 25, 2002, (the "Agreement"), pursuant to which the Investor has advanced certain funds to |
|
| March 30, 2004 |
DNAPrint genomics, Inc. Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) [ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| November 14, 2003 |
Ex-10.30 Termination Agreement Exhibit 10.30 TERMINATION AGREEMENT This Termination Agreement is entered into this day of , 2003, by and among DNAPrint Genomics, Inc., a Utah corporation (collectively, "DNAPrint"), and GenBiomics, LLC ("GenBiomics"). W I T N E S S E T H: WHEREAS, DNAPrint and GenBiomics are parties to a Consultant Agreement dated May 17, 2002 (the "Agreement"); and WHEREAS, the parties desire to terminate the A |
|
| November 14, 2003 |
EX-10.31 Lease with DNAPrint genomics, Inc. . . . Exhibit 10.31 LEASE AGREEMENT TABLE OF CONTENTS Article Heading Page - - - - 1. Premises 2. Term 3. Rent 4. Use 5. Maintenance 6. Surrender of Premises 7. Quiet Enjoyment 8. Assignment 9. Utilities and Taxes 10. Signage and Store Windows 11. Alteration to the Premises and Removal of Equipment 12. Liens 13. Casualty 14. Insurance 15. Indemnification 16. Inspection and Repair 17. Default 18. W |
|
| November 14, 2003 |
EX-10.32 Amendment to Consulting Agreement Exhibit 10.32 AMENDMENT This Amendment to Consulting and Marketing License Agreement is entered into as of the 18th day of June, 2003 by and between Mark Neuhaus (the "Consultant") and DNAPrint genomics, Inc. (the "Company"). W I T N E S S E T H: WHEREAS, the parties hereto are parties to a Consulting and Marketing License Agreement dated on or about November 8, 2001 (the "Agreement"); and WHEREAS |
|
| November 14, 2003 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB x Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended September 30, 2003. o Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-31905 DNAPrint gen |
|
| October 3, 2003 |
exv16 September 30, 2003 Securities and Exchange Commission Mail Stop 11-3 450 5th Street, N.W. Washington, D.C. 20549 Re: DNAPrint genomics, Inc. Dear Sirs/Madams: We have read the statements in Item 4 of Form 8-K of DNAPrint genomics, Inc. dated September 26, 2003. We agree with the statements concerning our firm in such Form 8-K. Yours truly, /s/ Kingery, Crouse & Hohl, P.A. |
|
| October 3, 2003 |
DNAPrint Genomics, Inc. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 1 to FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2003 DNAPRINT GENOMICS, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction or incorporation) 0-3190 |
|
| September 26, 2003 |
EXHIBIT 16 September 24, 2003 Securities and Exchange Commission Mail Stop 11-3 450 5th Street, N. |
|
| September 26, 2003 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2003 DNAPRINT GENOMICS, INC. |
|
| August 15, 2003 |
luchese063003agmt CONVERSION AGREEMENT This Conversion Agreement is made and entered into this day of May, 2003, by and between Jack J. |
|
| August 15, 2003 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended June 30, 2003. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-31905 DNAPrint genomics, Inc. (Exact |
|
| August 15, 2003 |
employmentagmtrg DNAPrint genomics, Inc. EMPLOYMENT AGREEMENT This Employment Agreement is made as of May 16, 2003 by and between DNAPrint genomics, Inc, a Utah corporation (the "Company") having its principal place of business at 900 Cocoanut Avenue, Sarasota, Fl 34234 and Richard Gabriel (the "Executive") currently residing at 20 Blodgett Avenue, Swampscott, MA 01907. BACKGROUND INFORMATION The |
|
| August 15, 2003 |
DNAPrint genomics, Inc. EMPLOYMENT AGREEMENT This Employment Agreement is made as of May 16, 2003 by and between DNAPrint genomics, Inc, a Utah corporation (the "Company") having its principal place of business at 900 Cocoanut Avenue, Sarasota, Fl 34234 and Monica Tamborini (the "Executive") currently residing at 20 Blodgett Avenue, Swampscott, MA 01907. BACKGROUND INFORMATION The Company wishes t |
|
| August 15, 2003 |
DNAPrint genomics, Inc. EMPLOYMENT AGREEMENT This Employment Agreement is made as of May 16, 2003 by and between DNAPrint genomics, Inc, a Utah corporation (the "Company") having its principal place of business at 900 Cocoanut Avenue, Sarasota, Fl 34234 and Hector Gomez (the "Executive") currently residing at 5105 Rue Vendome, Lutz, FL 33558. BACKGROUND INFORMATION The Company wishes to secure the |
|
| May 21, 2003 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB/A (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended March 31, 2003. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-30119 DNAPrint genomics, Inc. (Exa |
|
| May 21, 2003 |
sarbanesoxleyact Exhibit 99.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) In connection with this quarterly filing of DNAPrint genomics, Inc., a Utah corporation (the "Company"), on Form 10QSB for the quarter ending March 31, 2003, as filed with the Securities and Exchange Commission (the "Report"), I, Richard Gabriel, Chief Executive Officer an |
|
| May 20, 2003 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended March 31, 2003. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-30119 DNAPrint genomics, Inc. (Exact |
|
| May 20, 2003 |
Exhibit 99.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) In connection with this quarterly filing of DNAPrint genomics, Inc., a Utah corporation (the "Company"), on Form 10QSB for the quarter ending March 31, 2003, as filed with the Securities and Exchange Commission (the "Report"), I, Richard Gabriel, Chief Executive Officer and Principal Finan |
|
| May 15, 2003 |
dnap0303nt10q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 0-30119 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K/KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q/QSB [ ] Form N-SAR For the Period Ended: March 31, 2003 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Rep |
|
| April 15, 2003 |
Exhibit 99.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) In connection with this annual filing of DNAPrint genomics, Inc., a Utah corporation (the "Company"), on Form 10-KSB for the year ended December 31, 2002 as filed with the Securities and Exchange Commission (the "Report"), I, Richard Gabriel, Chief Executive Officer of the Company, certify |
|
| April 15, 2003 |
frudakis99exhibit Exhibit 99.2 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) In connection with this annual filing of DNAPrint genomics, Inc., a Utah corporation (the "Company"), on Form 10-KSB for the year ended December 31, 2002 as filed with the Securities and Exchange Commission (the "Report"), I, Tony Frudakis, Principal Financial Officer of |
|
| April 15, 2003 |
dnap10ksb2002 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2002 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-30119 DNAPrint genomi |
|
| March 31, 2003 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 0-30119 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K/KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q/QSB [ ] Form N-SAR For the Period Ended: December 31, 2002 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form |
|
| November 14, 2002 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended September 30, 2002. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-30119 DNAPrint genomics, Inc. (E |
|
| November 14, 2002 |
dnapfundingagmt FUNDING AGREEMENT THIS FUNDING AGREEMENT made this 25th day of October, 2002 by and among DNAPRINT GENOMICS, INC. |
|
| November 14, 2002 |
dnapexhibit99 Exhibit 99.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) In connection with this quarterly filing of DNAPrint genomics, Inc., a Utah corporation (the "Company"), on Form 10QSB for the quarter ending September 30, 2002 as filed with the Securities and Exchange Commission (the "Report"), I, Tony Frudakis, Chief Executive Officer and |
|
| August 14, 2002 |
June 17, 2002 This will confirm the terms of our mutual understanding and agreement ("Agreement") in connection with the efforts of ("Finder") to obtain financing for ("Company") as follows: 1. |
|
| August 14, 2002 |
LICENSE AGREEMENT This License Agreement, effective upon the date of last signature herein (the "Effective Date"), by and between The Penn State Research Foundation (hereinafter referred to as "PSRF"), a non-profit corporation duly organized and existing under the laws of the Commonwealth of Pennsylvania and having an office at 304 Old Main, University Park, PA 16802, and DNAPrint Genomics Inc, a corporation organized under the laws of the State of Florida (hereinafter referred to as "LICENSEE"), having its principal office at 900 Cocoanut Avenue, Sarasota, Florida 34236. |
|
| August 14, 2002 |
amendedgenbiomicagmt GENBIOMICS, LLC Investments for Pharmaceutical Research ADDENDUM 1. |
|
| August 14, 2002 |
dnap10qsbjune2002 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended June 30, 2002. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-30119 DNAPrint genom |
|
| August 14, 2002 |
shrivercommitmentletter Letter of Commitment To DNAPrint genomics, Inc. Scientific Advisory Board Date: Please accept this letter as my commitment to DNAPrint genomics, Inc. (the "Company") to act as a member of its Board of Directors (SAB). I hereby agree to serve as a member of the companies Board of Directors (BOD). I understand and agree that my commitment to the Company may include, but is no |
|
| August 14, 2002 |
SERVICES AGREEMENT This Agreement (the "Agreement"), dated April 15, 2002 (the "Effective Date"), is by and between DNA Print DNA Print Genomics, a Utah corporation having a principal place of business at 900 Cocoanut Ave, Sarasota, Florida 34236 (hereinafter "DNA Print"), and Altura, LLC, a California Limited Liability Altura having a principal place of business at 20 Bronco St. |
|
| August 14, 2002 |
GENBIOMICS, LLC Investments for Pharmaceutical Research CONSULTANT AGREEMENT THIS CONSULTANT AGREEMENT (the Agreement), is entered into effective as of Friday, 17 May 2002 (the Effective Date) by and between DNAPrint Genomics, Inc. |
|
| August 14, 2002 |
AMENDMENT TO CONSULTING CONTRACT THIS AMENDMENT is made this day of , 2002, by and between DNAPrint Genomics, Inc. |
|
| August 14, 2002 |
DNAPRINT/OSKAREP PRIVATE PLACEMENT AGREEMENT This Private Placement Agreement (this "Agreement") is made and entered into as of January , 2002 (the "Effective Date") by and between DNAprint genomics, a Utah corporation, (hereinafter "DNAPRINT") and John Oskarep (hereinafter "PARTY"). |
|
| August 14, 2002 |
shriverconsultingagreement DNAPRINT/MARK SHRIVER CONSULTING CONTRACT This Consulting Contract Agreement (this "Agreement") is made and entered into as of June 12, 2002 (the "Effective Date") by and between DNAprint genomics, a Utah corporation, (hereinafter "DNAPRINT") and Mark Shriver (hereinafter "CONSULTANT"). |
|
| May 15, 2002 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended March 31, 2002. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-30119 DNAPrint genomics, Inc. (Exact |
|
| April 9, 2002 |
DNAPRINT/GENOMED CONTRACT GENOTYPING AGREEMENT This Contract Genotyping Agreement (this "Agreement") is made and entered into as of January 15, 2002 (the "Effective Date") by and between DNAprint genomics, a Utah corporation, (hereinafter "DNAPRINT") and GenoMed LLC, a Delaware corporation (hereinafter "GENOMED"). |
|
| April 9, 2002 |
DNAPRINT GENOMICS, INC. Performance Stock Agreement This Performance Stock Agreement (the "Agreement"), effective as of November 30, 2001 is made by and between DNAPrint genomics, Inc., a Utah corporation (the "Company"), and Tony N. Frudakis, hereinafter referred to as the "Grantee". WHEREAS, The Company wishes to grant shares of the Company's common stock to the subject to certain conditions est |
|
| April 9, 2002 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2001 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-30119 DNAPrint genomics, Inc. (Name |
|
| April 9, 2002 |
CONSULTING AGREEMENT THIS AGREEMENT is made and entered into this 24th day of February 2002, between DNAprint genomics, Inc. |
|
| April 9, 2002 |
EX-10.19 7 stockpurchaseoption.htm STOCK PURCHASE OPTION SCHEDULE A OPTION TO PURCHASE 28,000,000 COMMON SHARES THIS OPTION AND THE SHARES ISSUABLE ON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND ARE RESTRICTED SECURITIES WITHIN THE MEANING OF SECURITIES ACT RULE 144. THEY MAY NOT BE SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED, DISPOSED OF OR OFFERED FOR S |
|
| April 9, 2002 |
AGREEMENT THIS AGREEMENT made the 22nd day of February, 2002 by and between TAMPA BAY FINANCIAL, INC. |
|
| April 9, 2002 |
FUNDING AGREEMENT THIS FUNDING AGREEMENT made this 25th day of February, 2002 by and among DNAPRINT GENOMICS, INC. |
|
| April 1, 2002 |
dnapnt10k U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 0-31905 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K/KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q/QSB [ ] Form N-SAR For the Period Ended: December 31, 2001 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Repo |
|
| November 15, 2001 |
marketinglicenseagreement CONSULTING AND MARKETING LICENSE AGREEMENT THIS CONSULTING AND MARKETING LICENSE AGREEMENT, (the "Agreement") is between Mark Neuhaus (the "Consultant") and DNAPrint genomics, Inc. |
|
| November 15, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended September 30, 2001. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-30119 DNAPrint genomics, Inc. (E |
|
| November 9, 2001 |
dnapforms8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DNAPrint genomics, Inc. (Exact Name of Registrant as Specified in its Charter) State of Utah 900 Cocoanut Avenue 59-2780520 Sarasota, FL 34231 (State or Other (Address, including zip (I.R.S. Employer Jurisdiction of code of principal Identification Inc |
|
| November 7, 2001 |
dnapforms8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DNAPrint genomics, Inc. (Exact Name of Registrant as Specified in its Charter) State of Utah 900 Cocoanut Avenue 59-2780520 Sarasota, FL 34231 (State or Other (Address, including zip (I.R.S. Employer Jurisdiction of code of principal Identification Inc |
|
| August 14, 2001 |
Applied Biosystems Financial Services May 18, 2001 Dr. Tony Frudakis DNAPrInt Genomics Inc. 900 Coconut Avenue Sarasota, FL 34236 Dear Dr. Frudakis, I am pleased to submit the following Finance Commitment for instrumentation manufactured by Applied Biosystems. LESSEE: DNAPrint genomics, Inc. INSTRUMENT: 3700 Refurb unit - as described on quotation #20120715 INSTRUMENT COST: $ 264,634.00 DOWN PAYME |
|
| August 14, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended June 30, 2001. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-30119 DNAPrint genomics, Inc. (Exact |
|
| August 14, 2001 |
Funding and Stock Subscription Agreement This Agreement, made and entered into this 8th day of June, 2001 by and between Tampa Bay Financial, Inc. |
|
| May 21, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-QSB (X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934. For the quarterly period ended March 31, 2001. ( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for the transition period from to . Commission File Number: 0-30119 DNAPrint genomics, Inc. (Exact |
|
| May 15, 2001 |
dnaprintform12b25 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 0-30119 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K/KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q/QSB [ ] Form N-SAR For the Period Ended: March 31, 2001 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition |
|
| May 14, 2001 |
Item4Exhibit Securities and Exchange Commision Washington, D.C. 20549 Gentlemen: We have read Item 4 of the Current Report on Form 8-K of DNAPrint genomics, Inc., as filed on May 9, 2001, and we agree with the statements contained therein insofar as they pertain to our firm. /s/ Howard R. Womeldorph, Jr. Howard R. Womeldorph, Jr. Sarasota, FL May 7, 2001 |
|
| May 14, 2001 |
dnapform8k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934. May 7, 2001 Date of Report (Date of Earliest Event Reported) DNAPrint genomics, Inc. (Exact name of registrant as specified in charter) Commission File Number: 0-30119 Utah 59-2780520 (State of Incorporation) (I.R.S. |
|
| April 27, 2001 |
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 - - 1. Name and Address of Reporting Person* Frudakis George - - (Last) (First) (Midd |
|
| April 25, 2001 |
Schedule13d SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| April 25, 2001 |
CHANGES IN BENEFICIAL OWNERSHIP Form 4 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 [] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may continu |
